Review



cgrp receptor antagonist  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    MedChemExpress cgrp receptor antagonist
    Cgrp Receptor Antagonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 46 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cgrp receptor antagonist/product/MedChemExpress
    Average 94 stars, based on 46 article reviews
    cgrp receptor antagonist - by Bioz Stars, 2026-06
    94/100 stars

    Images



    Similar Products

    cgrp receptor antagonist  (MedChemExpress)
    94
    MedChemExpress cgrp receptor antagonist
    Cgrp Receptor Antagonist, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cgrp receptor antagonist/product/MedChemExpress
    Average 94 stars, based on 1 article reviews
    cgrp receptor antagonist - by Bioz Stars, 2026-06
    94/100 stars
    		  Buy from Supplier
    cgrp receptor antagonist bibn4096bs  (Haoyuan Chemexpress Co Ltd)
    86
    Haoyuan Chemexpress Co Ltd cgrp receptor antagonist bibn4096bs
    CGRP Promotes Angiogenesis in HUVECs and Pulp Repair via Upregulation of CD31/VEGFA (A) Representative images of tube formation assays using HUVECs treated with or without CGRP. Scale bar, 500 µm. (n = 3, *p < 0.05, **p < 0.01 vs. NC group). (B) ​ Representative images of scratch wound healing assays of HUVECs at 0,12 and 24 h post-CGRP treatment and quantitative analysis of wound closure rate. Scale bar, 100 µm. (n = 3, *p < 0.05 vs. NC group). (C) ​ qRT-PCR and Western blot analysis of CD31 and VEGFA levels in HUVECs. (n = 3, **p < 0.01, ***p < 0.001 vs. NC group). (D) ​ Representative immunofluorescence images showing CD31 + blood vessels (red) in the injured pulp region of mice treated with either vehicle (NC) or the CGRP receptor antagonist <t>BIBN4096BS.</t> Nuclei are counterstained with DAPI (blue). Scale bar, 50 µm. Green dashed line, dentin injury (cavity). Green arrow, region of interest (ROI) in the pulp horn beneath the injury site, where vascular changes were analyzed. (E) ​ CGRP-activated endothelial cells promote the mineralization of DPSCs via a paracrine mechanism. (n = 3, **p < 0.01vs. NC group).
    Cgrp Receptor Antagonist Bibn4096bs, supplied by Haoyuan Chemexpress Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cgrp receptor antagonist bibn4096bs/product/Haoyuan Chemexpress Co Ltd
    Average 86 stars, based on 1 article reviews
    cgrp receptor antagonist bibn4096bs - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    small molecule cgrp receptor antagonist rimegepant  (Selleck Chemicals)
    93
    Selleck Chemicals small molecule cgrp receptor antagonist rimegepant
    CGRP Promotes Angiogenesis in HUVECs and Pulp Repair via Upregulation of CD31/VEGFA (A) Representative images of tube formation assays using HUVECs treated with or without CGRP. Scale bar, 500 µm. (n = 3, *p < 0.05, **p < 0.01 vs. NC group). (B) ​ Representative images of scratch wound healing assays of HUVECs at 0,12 and 24 h post-CGRP treatment and quantitative analysis of wound closure rate. Scale bar, 100 µm. (n = 3, *p < 0.05 vs. NC group). (C) ​ qRT-PCR and Western blot analysis of CD31 and VEGFA levels in HUVECs. (n = 3, **p < 0.01, ***p < 0.001 vs. NC group). (D) ​ Representative immunofluorescence images showing CD31 + blood vessels (red) in the injured pulp region of mice treated with either vehicle (NC) or the CGRP receptor antagonist <t>BIBN4096BS.</t> Nuclei are counterstained with DAPI (blue). Scale bar, 50 µm. Green dashed line, dentin injury (cavity). Green arrow, region of interest (ROI) in the pulp horn beneath the injury site, where vascular changes were analyzed. (E) ​ CGRP-activated endothelial cells promote the mineralization of DPSCs via a paracrine mechanism. (n = 3, **p < 0.01vs. NC group).
    Small Molecule Cgrp Receptor Antagonist Rimegepant, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/small molecule cgrp receptor antagonist rimegepant/product/Selleck Chemicals
    Average 93 stars, based on 1 article reviews
    small molecule cgrp receptor antagonist rimegepant - by Bioz Stars, 2026-06
    93/100 stars
    		  Buy from Supplier
    cgrp receptor antagonists  (Boehringer Ingelheim)
    86
    Boehringer Ingelheim cgrp receptor antagonists
    CGRP Promotes Angiogenesis in HUVECs and Pulp Repair via Upregulation of CD31/VEGFA (A) Representative images of tube formation assays using HUVECs treated with or without CGRP. Scale bar, 500 µm. (n = 3, *p < 0.05, **p < 0.01 vs. NC group). (B) ​ Representative images of scratch wound healing assays of HUVECs at 0,12 and 24 h post-CGRP treatment and quantitative analysis of wound closure rate. Scale bar, 100 µm. (n = 3, *p < 0.05 vs. NC group). (C) ​ qRT-PCR and Western blot analysis of CD31 and VEGFA levels in HUVECs. (n = 3, **p < 0.01, ***p < 0.001 vs. NC group). (D) ​ Representative immunofluorescence images showing CD31 + blood vessels (red) in the injured pulp region of mice treated with either vehicle (NC) or the CGRP receptor antagonist <t>BIBN4096BS.</t> Nuclei are counterstained with DAPI (blue). Scale bar, 50 µm. Green dashed line, dentin injury (cavity). Green arrow, region of interest (ROI) in the pulp horn beneath the injury site, where vascular changes were analyzed. (E) ​ CGRP-activated endothelial cells promote the mineralization of DPSCs via a paracrine mechanism. (n = 3, **p < 0.01vs. NC group).
    Cgrp Receptor Antagonists, supplied by Boehringer Ingelheim, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cgrp receptor antagonists/product/Boehringer Ingelheim
    Average 86 stars, based on 1 article reviews
    cgrp receptor antagonists - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier
    cgrp receptor antagonist platform  (Bristol Myers)
    86
    Bristol Myers cgrp receptor antagonist platform
    CGRP Promotes Angiogenesis in HUVECs and Pulp Repair via Upregulation of CD31/VEGFA (A) Representative images of tube formation assays using HUVECs treated with or without CGRP. Scale bar, 500 µm. (n = 3, *p < 0.05, **p < 0.01 vs. NC group). (B) ​ Representative images of scratch wound healing assays of HUVECs at 0,12 and 24 h post-CGRP treatment and quantitative analysis of wound closure rate. Scale bar, 100 µm. (n = 3, *p < 0.05 vs. NC group). (C) ​ qRT-PCR and Western blot analysis of CD31 and VEGFA levels in HUVECs. (n = 3, **p < 0.01, ***p < 0.001 vs. NC group). (D) ​ Representative immunofluorescence images showing CD31 + blood vessels (red) in the injured pulp region of mice treated with either vehicle (NC) or the CGRP receptor antagonist <t>BIBN4096BS.</t> Nuclei are counterstained with DAPI (blue). Scale bar, 50 µm. Green dashed line, dentin injury (cavity). Green arrow, region of interest (ROI) in the pulp horn beneath the injury site, where vascular changes were analyzed. (E) ​ CGRP-activated endothelial cells promote the mineralization of DPSCs via a paracrine mechanism. (n = 3, **p < 0.01vs. NC group).
    Cgrp Receptor Antagonist Platform, supplied by Bristol Myers, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cgrp receptor antagonist platform/product/Bristol Myers
    Average 86 stars, based on 1 article reviews
    cgrp receptor antagonist platform - by Bioz Stars, 2026-06
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    CGRP Promotes Angiogenesis in HUVECs and Pulp Repair via Upregulation of CD31/VEGFA (A) Representative images of tube formation assays using HUVECs treated with or without CGRP. Scale bar, 500 µm. (n = 3, *p < 0.05, **p < 0.01 vs. NC group). (B) ​ Representative images of scratch wound healing assays of HUVECs at 0,12 and 24 h post-CGRP treatment and quantitative analysis of wound closure rate. Scale bar, 100 µm. (n = 3, *p < 0.05 vs. NC group). (C) ​ qRT-PCR and Western blot analysis of CD31 and VEGFA levels in HUVECs. (n = 3, **p < 0.01, ***p < 0.001 vs. NC group). (D) ​ Representative immunofluorescence images showing CD31 + blood vessels (red) in the injured pulp region of mice treated with either vehicle (NC) or the CGRP receptor antagonist BIBN4096BS. Nuclei are counterstained with DAPI (blue). Scale bar, 50 µm. Green dashed line, dentin injury (cavity). Green arrow, region of interest (ROI) in the pulp horn beneath the injury site, where vascular changes were analyzed. (E) ​ CGRP-activated endothelial cells promote the mineralization of DPSCs via a paracrine mechanism. (n = 3, **p < 0.01vs. NC group).

    Journal: Frontiers in Cell and Developmental Biology

    Article Title: CGRP-mediated neuro-vascular-pulp cell crosstalk is essential for dental pulp repair

    doi: 10.3389/fcell.2026.1793692

    Figure Lengend Snippet: CGRP Promotes Angiogenesis in HUVECs and Pulp Repair via Upregulation of CD31/VEGFA (A) Representative images of tube formation assays using HUVECs treated with or without CGRP. Scale bar, 500 µm. (n = 3, *p < 0.05, **p < 0.01 vs. NC group). (B) ​ Representative images of scratch wound healing assays of HUVECs at 0,12 and 24 h post-CGRP treatment and quantitative analysis of wound closure rate. Scale bar, 100 µm. (n = 3, *p < 0.05 vs. NC group). (C) ​ qRT-PCR and Western blot analysis of CD31 and VEGFA levels in HUVECs. (n = 3, **p < 0.01, ***p < 0.001 vs. NC group). (D) ​ Representative immunofluorescence images showing CD31 + blood vessels (red) in the injured pulp region of mice treated with either vehicle (NC) or the CGRP receptor antagonist BIBN4096BS. Nuclei are counterstained with DAPI (blue). Scale bar, 50 µm. Green dashed line, dentin injury (cavity). Green arrow, region of interest (ROI) in the pulp horn beneath the injury site, where vascular changes were analyzed. (E) ​ CGRP-activated endothelial cells promote the mineralization of DPSCs via a paracrine mechanism. (n = 3, **p < 0.01vs. NC group).

    Article Snippet: The CGRP receptor antagonist BIBN4096BS was purchased from Shanghai Haoyuan Chemexpress Co. (Shanghai, China).

    Techniques: Quantitative RT-PCR, Western Blot, Immunofluorescence